Abstract: Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.

Abstract: A computing device is configured to perform acts that include displaying a graphical user interface (GUI) of an operating system installed on the computing device, where a taskbar of the GUI includes a search box. The search box includes: 1) a text entry field that is configured to receive textual input; and 2) a graphical icon. The acts also include detecting a selection of the text entry field and presenting a first graphical pane on the display in response to detecting the selection of the text entry field, where the first graphical pane includes first content. The acts also include detecting a selection of the graphical icon. The acts further include presenting a second graphical pane on the display in response to detecting the selection of the graphical icon, where the second graphical pane comprises second content that is different from the first content.

Abstract: Semiconductor fabrication component preparation methods are described. In embodiments, the methods include forming a first layer on a surface of the semiconductor fabrication component. The first layer is characterized by a porosity of greater than or about 0.01 vol. %. The methods further include depositing a second layer on the first layer, where the second layer is characterized by a porosity of less than or about 20 vol. %. Treated semiconductor fabrication components are also described. In embodiments, the treated components include a first layer formed in the surface of the semiconductor fabrication component, where the first layer is characterized by a porosity of greater than or about 0.01 vol. %., and a second layer positioned on the first layer, where the second layer is characterized by a porosity of less than or about 20 vol. %.

Abstract: A computer-implemented method for quantitative prediction and sorting of carbon underground treatment and sequestration is described. The method includes preprocessing multiple data sets, wherein the multiple datasets are multi-modal and multiscale data sets. The method also includes predicting geological structural properties, chemical properties, and geological properties by inputting the preprocessed multiple data sets into trained machine learning models. Additionally, the method includes ranking the storage and treatment potential of a formation based on the predicted geological structural properties, chemical properties, and geological properties.

Abstract: The subject matter of this specification can be embodied in, among other things, a method for treating a geologic formation that includes providing a hydraulic fracture model, providing a first value representative of a volume of kerogen breaker in a fracturing fluid, determining a discrete fracture network (DFN) based on the hydraulic fracture model and the first value, determining a geomechanical model based on the DFN and a reservoir model based on the DFN, determining a hydrocarbon production volume based on the geomechanical model and the reservoir model, adjusting the first value based on the hydrocarbon production volume, and adjusting a volume of kerogen breaker in the fracturing fluid to a hydrocarbon reservoir based on the adjusted first value.

Abstract: DCAF15 is a substrate recognition (adaptor) protein of E3 ubiquitin ligase. Disclosed herein are compounds that recruit ubiquitin ligase CRL4DCAF15, to a target RNA recognition motif (RRM), causing its degradation. Also disclosed herein are compositions and methods of use in treating associated disorders and diseases.

Abstract: Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.

Abstract: Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.

Abstract: Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.

Abstract: Described are methods and compositions for clinically proven safe and effective treatment of ulcerative colitis according to the product label described herein, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.

Abstract: Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.

Abstract: Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.

Abstract: Methods and kits are provided for the assessment of the suitability of and/or effectiveness of a target therapy for a TNF mediated-related disorder, such as ulcerative colitis, in a subject, which methods and kits evaluate the presence, absence, and/or magnitude of expression of two or more genes up or down regulated in association with anti-TNF responders in inflammatory gastrointestinal disorders, such as ulcerative colitis, with at least two genes including BCL6 (Genbank Acc. No. AW264036; SEQ ID NO:118) and tx82a04.x1 (Genbank Acc. No. AI689210; SEQ ID NO:123), optionally further comprising at least one to three of C5AR1 ((Genbank Acc. No.NM001736; SEQ ID NO: 119), FOLR1 ((Genbank Acc. No. U81501; SEQ ID NO: 142) and OSM (Genbank Acc. No. A1079327; SEQ ID NO: 173), optionally further comprising at least one of the listed genes presented in FIG. 7 with a therapeutic response to at least one anti-TNF? agents (e.g.

Abstract: Methods and kits for the assessment of the suitability of and/or effectiveness of a target therapy for a TNF mediated-related disorder, such as ulcerative colitis, in a subject, which methods and kits evaluate the presence, absence, and/or magnitude of expression of two or more genes up or down regulated in association with anti-TNF responders in inflammatory gastrointestinal disorders, such as ulcerative colitis

Abstract: Compositions and methods are provided for measuring and determining biomarkers for IL-13.

Abstract: A method for assessment of the suitability of a target therapy for a gastrointestinal-related disorder, such as ulcerative colitis, in a subject evaluates the presence, absence, and/or magnitude of expression of one or more genes in a 20- or 5-member gene panel in a sample. The method enables identification of the effectiveness of target therapies prior to starting a patient on such therapies.

Abstract: Compositions and methods are provided for measuring and determining biomarkers for IL-13.

Abstract: The invention provides isolated nucleic acids encoding a variety of nucleic acids and proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic acids and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acids molecules, expression vectors containing the nucleic acids molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acids molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.